Pearl River Capital’s Novavax NVAX Stock Holding History

Pearl River Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,584	Closed	-$559K	–	525
2022 Q1	$559K	Buy	7,584 +5,722	+307%	+$510K	0.15%	209
2021 Q4	$266K	Buy	+1,862	New	+$320K	0.07%	322
2021 Q2	–	Sell	-1,554	Closed	-$282K	–	530
2021 Q1	$282K	Buy	+1,554	New	+$310K	0.09%	297
2020 Q4	–	Sell	-2,223	Closed	-$241K	–	466
2020 Q3	$241K	Buy	+2,223	New	+$271K	0.1%	307

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Pearl River Capital's NVAX Position: Q2 2022 in Review

Pearl River Capital sold out of Novavax (NVAX) in Q2 2022, closing a stake of 7,584 shares — an estimated $559K sold.

Pearl River Capital first reported a position in NVAX in Q3 2020 and held it in 4 quarters. The position peaked at $559K in Q1 2022. 325 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

Pearl River Capital reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
Pearl River Capital sold 7,584 Novavax shares in Q2 2022, an estimated $559K.
Pearl River Capital first reported a position in Novavax in Q3 2020 and held it in 4 quarters.
Pearl River Capital's Novavax position peaked at $559K in Q1 2022.
325 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on Pearl River Capital's 13F filing for Q2 2022, filed 12 Aug 2022.